Urolithin A vs Fisetin: Which Is Better for Longevity?

Photo by Murat Ts. on Unsplash

By The Longevity Dose Editorial Team · Evidence-reviewed · Last updated July 2026

Urolithin A and fisetin are two of the most talked-about longevity supplements in 2026, and for good reason: both have more legitimate human research behind them than most compounds in the space. But the comparison of urolithin A vs fisetin matters because they work through completely different mechanisms, cost a real amount of money, and serve different biological purposes. If you’re trying to decide which one deserves a spot in your supplement stack, the answer depends on what the evidence actually says, not what the marketing claims.

What Is Urolithin A and What Does the Evidence Show?

Urolithin A is a compound your gut bacteria produce when you eat pomegranates, walnuts, or certain berries. The catch: roughly 30-40% of people don’t have the right gut microbiome to produce it at all. That’s part of why supplementing directly became interesting to researchers in the first place.

Its primary mechanism is mitophagy, the cellular process of clearing out damaged mitochondria so healthier ones can take their place. Think of it as a quality-control system for your cells’ power plants. As you age, mitophagy slows down, damaged mitochondria accumulate, and energy production drops. This is one of the recognized hallmarks of aging, and urolithin A appears to directly target it.

What Human Trials Actually Found

This is where urolithin A separates itself from most longevity supplements. A randomized controlled trial published in Nature Metabolism (Andreux et al., 2019) gave 500mg or 1000mg of urolithin A (as Mitopure) to healthy older adults aged 65-90 for four months. Researchers found significant improvements in muscle endurance, specifically in the number of hand-grip repetitions participants could perform. Molecular markers of mitophagy also improved in skeletal muscle biopsies.

A 2022 follow-up RCT in JAMA Network Open expanded this to middle-aged adults and confirmed the mitochondrial biomarker improvements were dose-dependent. These aren’t animal studies. These are double-blind, placebo-controlled human trials, the gold standard. That matters enormously in a supplement space full of mouse data dressed up as human evidence.

Urolithin A also shows up in anti-aging phytochemical research alongside fisetin. A 2024 review in Critical Reviews in Food Science and Nutrition (PMID 36597655) surveyed dietary compounds with anti-aging potential across multiple model organisms and humans, noting that mitophagy-activating compounds showed consistent benefits from animal models through to human trial outcomes, though the authors cautioned that lifespan extension in humans remains unproven.

Practical Use and Dosing

The clinically studied dose is 500mg daily of pharmaceutical-grade urolithin A (Mitopure is the branded form used in trials). Lower-dose supplements exist, but they haven’t been tested in RCTs. You can also get some urolithin A precursors by eating pomegranate daily, but production varies widely by individual gut microbiome composition.

Honest Downsides

Cost is the main barrier: pharmaceutical-grade urolithin A runs $60-$100 per month. Long-term effects beyond six months in humans aren’t well-studied yet. And while the mitochondrial data is real, no human study has shown it actually extends lifespan. That’s an important distinction to hold.

What Is Fisetin and What Does the Evidence Show?

Fisetin is a flavonoid found in strawberries, apples, persimmons, and onions. It belongs to a class of compounds called senolytics, which work by selectively clearing senescent cells, the so-called “zombie cells” that accumulate with age and drive chronic inflammation. If you want a deeper primer on how senescent cells fuel aging, our guide on what senolytics do to zombie cells covers the full mechanism.

Fisetin also activates autophagy, inhibits mTOR, and has demonstrated anti-inflammatory and neuroprotective properties in lab models. On paper, it looks remarkable. But here’s where honest assessment matters: most of fisetin’s most impressive results come from animal studies.

The Mouse Data vs Human Reality

The landmark fisetin study, published in EBioMedicine (Yousefzadeh et al., 2018) from the Mayo Clinic lab of Dr. James Kirkland, found that fisetin reduced senescent cell burden in multiple tissues of old mice and extended median lifespan by about 10%. That’s a real, reproducible result in mice. But mice are not people, and translating senolytic results to humans has proven consistently harder than researchers hoped.

Human data for fisetin specifically is sparse. A 2021 pilot study from the Mayo Clinic tested high-dose fisetin (20mg/kg for two days, then repeated) in older adults with frailty markers and found some reductions in inflammatory markers, but the sample size was small (n=40) and the trial wasn’t powered to show clinical outcomes. More human trials are underway, but as of mid-2026, none have replicated the mouse lifespan data in people.

A 2022 review in Plant Foods for Human Nutrition (PMID 35025006) highlighted fisetin among phytochemicals with promising longevity-related metabolic effects, but noted the same honest caveat: evidence from worm, fly, and rodent models needs to be confirmed in human trials before firm recommendations can be made.

Practical Use and Dosing

Human trials have used pulsed dosing protocols, not daily supplementation. The Mayo Clinic pilot used 20mg/kg body weight for two consecutive days, repeated monthly. For a 75kg adult, that’s roughly 1500mg per dose, far above what standard capsules provide. Daily low-dose fisetin (100-200mg) is popular in longevity circles, but that specific protocol hasn’t been tested in humans in a controlled trial. Bioavailability is also poor without fat or specialized delivery formats.

Honest Downsides

Fisetin’s evidence base lags meaningfully behind urolithin A when it comes to human clinical data. The dosing question is genuinely unresolved. And you should know that high-dose fisetin studies in cancer cell lines (including a 2021 paper in Molecules, PMID 34641401) showed antiproliferative activity in vitro, but these are lab findings, not evidence of safety or efficacy in people at similar doses.

Head-to-Head Comparison: Urolithin A vs Fisetin

The Verdict: Which One Should You Actually Take?

If you can only choose one, urolithin A wins for most people over 40. The human trial evidence is simply stronger. You’re not extrapolating from mice. You’re looking at double-blind RCTs showing real improvements in muscle endurance and mitochondrial biomarkers in people your age. For anyone concerned about muscle loss as they get older, which connects directly to why muscle mass is so predictive of longevity, urolithin A addresses a mechanism with confirmed human-level evidence.

Fisetin is genuinely interesting. The science is real and the mouse lifespan data is among the most compelling in the senolytic space. But “interesting mouse data” is the story of too many longevity supplements that never panned out in humans. Fisetin may well deliver on its promise once larger human trials complete. Right now, though, you’d be betting on biology that hasn’t been confirmed in people.

That said, there’s a reasonable case for taking both if budget allows, because they target completely different processes. Urolithin A cleans up dysfunctional mitochondria. Fisetin targets senescent cells. Neither one does the other’s job. If your priority is mitochondrial health and physical performance, start with urolithin A. If you’re specifically interested in senolytic interventions and you understand you’re working with early-stage human evidence, fisetin’s pulsed protocol (not daily low-dose) is the approach closest to what researchers actually tested.

Either way, both supplements sit firmly in the “promising but not proven to extend human lifespan” category. That’s the honest answer. Evidence shows urolithin A produces measurable biological changes in humans. Evidence does not yet show it adds years to your life. The same is true, more emphatically, for fisetin. This is a space worth watching, not one where you bet your health strategy on incomplete data. If you want the full picture of what’s worth stacking, our complete longevity supplement stack comparison for 2026 covers where both of these fit alongside other compounds.

One practical note: if you’re considering urolithin A, the Mitopure form (from Amazentis) is the one used in the actual RCTs. Generic urolithin A supplements may use different formulations with different absorption profiles. That’s not a sponsored opinion; it’s just an accuracy point that matters when you’re trying to replicate what a real study did.

For broader context on how these compounds fit into a science-backed longevity supplement strategy, Dr. Peter Attia’s blog and the NIH National Institute on Aging both maintain updated reviews of aging biology that can help you track where the evidence is heading.

Affiliate Disclosure: The Longevity Dose may earn a small commission if you purchase through the links below, at no additional cost to you. We only recommend products we genuinely believe in. Learn more.

Frequently Asked Questions

Is urolithin A better than fisetin for longevity?

Based on current human evidence, urolithin A has stronger clinical trial support, including two randomized controlled trials showing improvements in muscle endurance and mitochondrial biomarkers in people. Fisetin’s most compelling data comes from mouse studies, with only one small human pilot trial published as of 2026. For most people over 40, urolithin A is the more evidence-backed choice right now.

Can you take urolithin A and fisetin together?

There’s no known interaction between urolithin A and fisetin, and they work through distinct mechanisms: mitophagy activation versus senolytic clearance of zombie cells. Taking both together is practiced in some longevity circles, but no clinical trial has tested the combination. If you do use both, the standard approach is daily urolithin A and pulsed fisetin (two consecutive high-dose days per month), not daily low-dose fisetin.

What is the correct dose of fisetin for senolytic effects?

The closest thing to a tested human protocol is 20mg per kilogram of body weight for two consecutive days, repeated monthly, based on the Mayo Clinic pilot study from Dr. James Kirkland’s lab. For a 75kg adult, that’s approximately 1500mg per dose. Daily supplementation at 100-200mg is popular but hasn’t been validated in human clinical trials. Take it with fat to improve its notoriously poor bioavailability.

How long does urolithin A take to work?

In the Nature Metabolism RCT, meaningful improvements in muscle endurance and mitochondrial gene expression markers appeared after four months of daily supplementation at 500-1000mg. Don’t expect quick results. Mitophagy upregulation is a slow, cumulative biological process, not an acute effect you’ll feel within days.

Can you get enough fisetin or urolithin A from food?

Fisetin is highest in strawberries (about 160mcg per gram), but you’d need to eat unrealistic quantities to approach therapeutic doses. Urolithin A is produced by your gut bacteria from pomegranate ellagitannins, but 30-40% of people lack the microbiome capacity to produce it effectively, making food sources unreliable. This is the primary reason researchers developed direct supplementation with pharmaceutical-grade urolithin A.

Does fisetin actually clear senescent cells in humans?

The Mayo Clinic pilot study (n=40 older adults) found some reductions in circulating senescent cell markers and inflammatory cytokines after high-dose fisetin. However, the trial was small, not powered for clinical endpoints, and didn’t measure actual senescent cell counts in tissue. Larger, better-powered human trials are needed before we can say definitively that fisetin clears senescent cells in humans the way it does in mice.